Drug industry faces era of moderate price increases, says Valeant CEO

New York

VALEANT Pharmaceuticals International, which has been criticised for raising drug prices and is being investigated by the US government, predicted this week that lower price increases are ahead for the whole industry.

Valeant chief executive J Michael Pearson told investors on Monday that the company's 2016 outlook is based on expectations for a new pricing environment where none of its drugs have an actual price increase of more than 10 per cent.